Lenvatinib dose, efficacy, and safety in the treatment of multiple malignancies Review
| Authors: | Motzer, R. J.; Taylor, M. H.; Evans, T. R. J.; Okusaka, T.; Glen, H.; Lubiniecki, G. M.; Dutcus, C.; Smith, A. D.; Okpara, C. E.; Hussein, Z.; Hayato, S.; Tamai, T.; Makker, V. |
| Review Title: | Lenvatinib dose, efficacy, and safety in the treatment of multiple malignancies |
| Abstract: | Introduction: Lenvatinib is an oral multitargeted tyrosine kinase inhibitor that has shown efficacy and manageable safety across multiple cancer types. The recommended starting doses for lenvatinib differ across cancer types and indications based on whether it is used as monotherapy or as combination therapy. Areas covered: This review covers clinical trials that established the dosing paradigm and efficacy of lenvatinib and defined its adverse-event profile as a monotherapy; or in combination with the mTOR inhibitor, everolimus; or the anti-PD-1 antibody, pembrolizumab; and/or chemotherapy. Expert opinion: Lenvatinib has been established as standard-of-care either as a monotherapy or in combination with other anticancer agents for the treatment of radioiodine-refractory differentiated thyroid carcinoma, hepatocellular carcinoma, renal cell carcinoma, and endometrial carcinoma, and is being investigated further across several other tumor types. The dosing and adverse-event management strategies for lenvatinib have been developed through extensive clinical trial experience. Collectively, the data provide the rationale to start lenvatinib at the recommended doses and then interrupt or dose reduce as necessary to achieve required dose intensity for maximized patient benefit. The adverse-event profile of lenvatinib is consistent with that of other tyrosine kinase inhibitors, and clinicians are encouraged to review and adopt relevant symptom-management strategies. © 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. |
| Keywords: | hepatocellular carcinoma; antineoplastic agents; liver neoplasms; antineoplastic agent; protein kinase inhibitor; pathology; renal cell carcinoma; kidney neoplasms; protein kinase inhibitors; radioactive iodine; kidney tumor; carcinoma, renal cell; iodine radioisotopes; liver tumor; safety; thyroid carcinoma; thyroid neoplasms; endometrial carcinoma; thyroid tumor; dosing; tki; quinolines; quinoline derivative; phenylurea compounds; lenvatinib; carbanilamide derivative; humans; human; pembrolizumab |
| Journal Title: | Expert Review of Anticancer Therapy |
| Volume: | 22 |
| Issue: | 4 |
| ISSN: | 1473-7140 |
| Publisher: | Taylor & Francis Group |
| Date Published: | 2022-01-01 |
| Start Page: | 383 |
| End Page: | 400 |
| Language: | English |
| DOI: | 10.1080/14737140.2022.2039123 |
| PUBMED: | 35260027 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Article -- Export Date: 2 May 2022 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work